XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Ordinary shares
Preferred shares
Additional paid-in capital
Additional paid-in capital
Cumulative Effect, Period of Adoption, Adjustment
Accumulated deficit
Accumulated deficit
Cumulative Effect, Period of Adoption, Adjustment
Accumulated other comprehensive (loss) income
Beginning balance (in shares) at Dec. 31, 2020     58,396 488          
Beginning balance at Dec. 31, 2020 $ 162,266 $ (12,939) $ 583 $ 5 $ 566,916 $ (26,699) $ (384,187) $ 13,760 $ (21,051)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss (13,445)           (13,445)    
Other comprehensive loss (1,255)               (1,255)
Exercise of stock options (in shares)     23            
Exercise of stock options 106       106        
Vesting of restricted shares (in shares)     61            
Vesting of restricted shares 0   $ 1   (1)        
Employee share purchase plan share issuance (in shares)     8            
Employee share purchase plan share issuance 43       43        
Stock-based compensation expense 1,728       1,728        
Ending balance (in shares) at Mar. 31, 2021     58,488 488          
Ending balance at Mar. 31, 2021 136,504   $ 584 $ 5 542,093   (383,872)   (22,306)
Beginning balance (in shares) at Dec. 31, 2021     58,620 488          
Beginning balance at Dec. 31, 2021 78,244   $ 586 $ 5 549,349   (447,756)   (23,940)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss (26,424)           (26,424)    
Other comprehensive loss (1,102)               (1,102)
Exercise of stock options (in shares)     275            
Exercise of stock options 1,906   $ 3   1,903        
Vesting of restricted shares (in shares)     119            
Vesting of restricted shares 0   $ 1   (1)        
Employee share purchase plan share issuance (in shares)     18            
Employee share purchase plan share issuance 103       103        
Stock-based compensation expense 2,505       2,505        
Ending balance (in shares) at Mar. 31, 2022     59,032 488          
Ending balance at Mar. 31, 2022 $ 55,232   $ 590 $ 5 $ 553,859   $ (474,180)   $ (25,042)